Literature DB >> 8944457

Sequential systemic platelet-activating factor and interleukin 8 primes neutrophils in patients with trauma at risk of multiple organ failure.

A J Botha1, F A Moore, E E Moore, V M Peterson, C C Silliman, A W Goode.   

Abstract

Plasma from 33 patients at risk of multiple organ failure (MOF) after major trauma was tested for a priming effect on neutrophils, and for the presence of platelet-activating factor (PAF) activity and interleukin (IL) 8. Plasma sampled at 3, 6, 12 and 24 h after injury significantly primed normal neutrophils to release mean(s.e.m.) 1.26(0.19), 1.33(0.26), 1.04(0.14) and 0.86(0.13) nmol superoxide per min per 1.3 x 10(6) neutrophils respectively (P < 0.05). Priming at 3 h after injury was inhibited by mean(s.e.m.) 63.8(7.0) per cent by the PAF antagonist, WEB 2170 (P < 0.01). Mean(s.e.m.) plasma IL-8 was raised at 6 and 12 h after injury to 785(183) and 836(175) pg/ml (P < 0.01). At 12 h after injury the plasma IL-8 level correlated directly with the number of units of red blood cells transfused (r = 0.64, P < 0.01), and was significantly higher in the group of six patients who developed MOF (P < 0.05). These data suggest that after trauma the mediators PAF and IL-8 appear sequentially in the circulation, are potential mechanisms of circulating neutrophil priming, and that IL-8 may also be an early biochemical marker predicting the onset of MOF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8944457     DOI: 10.1002/bjs.1800831027

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  8 in total

1.  Role of E-selectin in bleomycin induced lung fibrosis in mice.

Authors:  A Azuma; S Takahashi; M Nose; K Araki; M Araki; T Takahashi; M Hirose; H Kawashima; M Miyasaka; S Kudoh
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

Review 2.  Trauma and the immune response.

Authors:  R M Smith; P V Giannoudis
Journal:  J R Soc Med       Date:  1998-08       Impact factor: 5.344

3.  Blood clotting and traumatic injury with shock mediates complement-dependent neutrophil priming for extracellular ROS, ROS-dependent organ injury and coagulopathy.

Authors:  C D Barrett; A T Hsu; C D Ellson; B Y Miyazawa; Y-W Kong; J D Greenwood; S Dhara; M D Neal; J L Sperry; M S Park; M J Cohen; B S Zuckerbraun; M B Yaffe
Journal:  Clin Exp Immunol       Date:  2018-09-09       Impact factor: 4.330

4.  Endothelial oxidative stress induced by serum from patients with severe trauma hemorrhage.

Authors:  Christian Laplace; Olivier Huet; Eric Vicaut; Catherine Ract; Laurent Martin; Dan Benhamou; Jacques Duranteau
Journal:  Intensive Care Med       Date:  2005-07-28       Impact factor: 17.440

5.  Prospective, randomized comparison of epidural versus parenteral opioid analgesia in thoracic trauma.

Authors:  M R Moon; F A Luchette; S W Gibson; J Crews; G Sudarshan; J M Hurst; K Davis; J A Johannigman; S B Frame; J E Fischer
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

Review 6.  Aging and animal models of systemic insult: trauma, burn, and sepsis.

Authors:  Vanessa Nomellini; Christian R Gomez; Richard L Gamelli; Elizabeth J Kovacs
Journal:  Shock       Date:  2009-01       Impact factor: 3.454

Review 7.  Insights into the Role of Chemokines, Damage-Associated Molecular Patterns, and Lymphocyte-Derived Mediators from Computational Models of Trauma-Induced Inflammation.

Authors:  Rami A Namas; Qi Mi; Rajaie Namas; Khalid Almahmoud; Akram M Zaaqoq; Othman Abdul-Malak; Nabil Azhar; Judy Day; Andrew Abboud; Ruben Zamora; Timothy R Billiar; Yoram Vodovotz
Journal:  Antioxid Redox Signal       Date:  2015-12-10       Impact factor: 8.401

Review 8.  Therapeutic Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in the Prevention of Organ Injuries Induced by Traumatic Hemorrhagic Shock.

Authors:  Guillaume Valade; Nicolas Libert; Christophe Martinaud; Eric Vicaut; Sébastien Banzet; Juliette Peltzer
Journal:  Front Immunol       Date:  2021-09-29       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.